Lucas Van Aelst
Overview
Explore the profile of Lucas Van Aelst including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
28
Citations
112
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Van der Vorst A, Lambrecht M, Van Aelst L, Verhoeven J, Jacobs J, Baten A, et al.
Strahlenther Onkol
. 2025 Feb;
PMID: 39976674
Background: Breast cancer is the most prevalent cancer in women worldwide; nevertheless, the prognosis is good, with a 5-year overall survival of 80-90%. Therefore, it becomes crucial to strive for...
2.
Rosseel T, Santens B, Droogne W, Voros G, Van Cleemput J, Van Aelst L, et al.
Int J Cardiol Congenit Heart Dis
. 2024 Dec;
8:100365.
PMID: 39712050
Patients with a systemic right ventricle (sRV) have a high risk of developing heart failure (HF), with heart transplantation as the only long-term treatment option. Unfortunately, more than half of...
3.
Van der Linden L, Van Aelst L, Olivotto I
Eur Heart J Cardiovasc Pharmacother
. 2024 Nov;
11(1):92-93.
PMID: 39545360
No abstract available.
4.
Casteur L, Rosseel T, Van Kerrebroeck M, Van Aelst L, Ector J
Eur Heart J Case Rep
. 2024 Oct;
8(10):ytae539.
PMID: 39445104
Background: Sarcoidosis is a rare disease, and cardiac involvement is seen in the minority of patients. The clinical symptoms depend on the location of the noncaseating granulomas in the heart...
5.
Van der Linden L, Van Aelst L
Curr Pharm Teach Learn
. 2024 May;
16(8):102114.
PMID: 38810348
Introduction: The pharmacy profession faces a lack of evidence pertaining to pharmaceutical care in oncology, both in terms of its effectiveness and its integration into clinical practice. While Europe-based pharmacists...
6.
Vanderstuyft E, Hias J, Hellemans L, Van Aelst L, Tournoy J, Van der Linden L
Eur J Hosp Pharm
. 2024 Apr;
PMID: 38580430
Background: Atrial fibrillation occurs in nearly half of geriatric inpatients and is a major cause of morbidity and mortality. Suboptimal anticoagulation use is an important concern in this population. This...
7.
Van der Linden L, Vanassche T, Van Aelst L, Verhamme P
Clin Pharmacokinet
. 2024 Jan;
63(3):395-396.
PMID: 38236563
No abstract available.
8.
Jacobs J, Greason G, Mangold K, Wildiers H, Willems R, Janssens S, et al.
Eur J Prev Cardiol
. 2023 Nov;
31(5):560-566.
PMID: 37943680
Aims: Cardiotoxicity is a serious side effect of anthracycline treatment, most commonly manifesting as a reduction in left ventricular ejection fraction (EF). Early recognition and treatment have been advocated, but...
9.
Van der Linden L, Hias J, Walgraeve K, Petrovic M, Tournoy J, Vandenbriele C, et al.
Drugs Aging
. 2023 Jul;
40(8):691-702.
PMID: 37452262
Heart failure is a prevalent syndrome among older adults, with a major impact on morbidity and mortality. Higher age is correlated with underuse of guideline-directed medical therapies which, in turn,...
10.
Van der Linden L, Vanassche T, Van Cutsem E, Van Aelst L, Verhamme P
Br J Clin Pharmacol
. 2023 May;
89(8):2369-2376.
PMID: 37170893
Drug-drug interactions (DDIs) are common in cancer management and complicate the choice of anticoagulation in cancer-associated thrombosis. Cancer confers an increased risk of thrombotic events. Also, more bleeding events are...